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Mycophenolate mofetil ameliorates nephropathy in the obese
Zucker rat.
Background. The obese Zucker rat has metabolic condition
resembling type II diabetes, including hyperlipidemia, obesity,
insulin resistance, and hyperglycemia. With advancing age, the
obese Zucker rat develops glomerulosclerosis, proteinuria, and
renal failure. Since immune cells play a central role in the de-
velopment of chronic renal injury, we evaluated the potential
benefit of mycophenolate mofetil (MMF), alone and in combi-
nation with angiotensin receptor type 1 blockade (ARB) in the
obese Zucker rat.
Methods. Thirteen-week-old male obese Zucker rats (fa/fa)
were randomly assigned to four experimental groups (five rats
each) that received the following treatments for 3 months: (1)
losartan (100 mg/L in the drinking water), (2) MMF (20 mg/
kg/day), (3) MMF and losartan, and (4) placebo. Lean Zucker
rats (N = 5) were included as normal controls. Renal function,
biochemical parameters, renal histology, and immunohistology
were evaluated.
Results. The placebo-treated obese Zucker rats exhibited
proteinuria and significant glomerular and tubulointerstitial in-
jury in association with renal immune cell infiltration. Protein-
uria, histologic damage, and renal immune cell infiltration were
all reduced by MMF treatment alone or in combination with
ARB. The improvement of proteinuria and structural damage
was more pronounced in the group that received the combina-
tion of MMF and losartan.
Conclusion. MMF treatment alone, and especially in combi-
nation with ARB, improves nephropathy in the obese Zucker
rat.
The metabolic features of type II diabetes associated
with obesity (type IIb) are present in the obese Zucker
rat (fa/fa rat), in which a recessive mutation of the gene
encoding the leptin receptor, results in hyperphagia, obe-
sity, insulin resistance hyperlipidemia, and hyperglycemia
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[1–3]. With advancing age, the obese Zucker rat develops
focal segmental glomerulosclerosis, proteinuria, and re-
nal failure [4]. Therefore, the obese Zucker rat is a widely
used model to study the characteristics of renal damage in
noninsulin-dependent diabetes mellitus which presently
represents the most important cause of end-stage renal
disease (ESRD) worldwide.
Previous studies have shown that the renal lesion of
the obese Zucker rat can be improved with hypolipidemic
treatments [5], angiotensin-converting enzyme (ACE) in-
hibition [6], and with dual use of angiotensin receptor
type 1 blocker and ACE inhibitor [7]. Congruent with
the beneficial effects of suppressing the angiotensin sys-
tem, recent results from our group indicate that the obese
Zucker rats have renal up-regulation of angiotensin
type 1 receptors and inflammatory mediators [8]. The
present studies examine another potential treatment of
the nephropathy in the obese Zucker rat: the immune
suppressive drug mycophenolate mofetil (MMF). The
justification for this strategy was based on the observa-
tions cited below.
Previous studies have demonstrated that mono-
cyte/macrophage influx precedes the development of
glomerulosclerosis in the obese Zucker rat [9]. Since
these cells play a central role in the pathogenesis of
chronic renal injury in various other models [10], it is
likely that they may also be involved in the pathogene-
sis of nephropathy in obese Zucker rats. Several inves-
tigations have demonstrated that administration of the
immunosuppressive drug MMF prevents or reduces the
glomerulosclerosis and tubulointerstitial damage in non-
immune models of progressive nephropathy [11, 12]. Of
particular relevance to the present studies are the find-
ings that MMF is beneficial in streptozotocin-induced di-
abetic nephropathy [13]. Furthermore, the combination
of MMF and angiotensin type 1 receptor blocker has been
shown to arrest progression of chronic renal failure in the
renal ablation model [14, 15]. Therefore, we designed the
present studies to determine if MMF alone or in com-
bination with the angiotensin type 1 receptor blocker,
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losartan, is beneficial in prevention of nephropathy of
the obese Zucker rat.
METHODS
Experimental animals
Studies were done in male obese (fa/fa) and lean (Fa/fa)
Zucker rats purchased from Charles River Charles River
Laboratories, Inc. (Wilmington, MA, USA). They were
housed in temperature controlled institutional facilities
with 12-hour cycles of light and darkness and had free
access to regular rat chow and water. The protocol of
the study was approved by institutional Animal Care and
Use Committees of the University of California, Irvine.
Experiments were started when rats were 13 weeks of
age. After determining baseline biochemical parameters
obese Zucker rats were randomly assigned to receive the
angiotensin receptor blocker losartan (N = 5), MMF
(N = 5), both losartan and MMF (N = 5) or vehicle
(obese Zucker rat group) (N = 5). Losartan was given
in the drinking water (100 mg/L) and MMF was given by
gastric gavage (20 mg/kg/day) as in previous communica-
tions [8, 12], in the corresponding groups for a period of
3 months. Male lean Zucker rats (N = 5) of similar age
were used as a control group.
Body weight, systolic blood pressure (tail-cuff plethys-
mography), proteinuria, plasma creatinine, cholesterol,
triglycerides, and blood sugar were determined prior to
the experiments in five obese Zucker rats and in five lean
Zucker rats and in all the rats from the experimental and
control groups prior to sacrifice.
At the end of the study, the animals were anesthesized
with intraperitoneal sodium pentobarbital (Nembutal)
(50 mg/kg,) and kidneys were harvested after perfusion
with cold (4◦C) saline and fixed and prepared for light
microscopy and immunohistology.
Histology and immunohistology
All histologic and immunohistologic studies were done
without previous knowledge of the experimental group
being examined. Light microscopy studies were done
in formalin-fixed, paraffin-embedded kidney sections
stained with periodic acid-Schiff (PAS) and hematoxylin
and eosin stainings. Proliferation, mesangial expansion,
and glomerulosclerosis (segmental collapse and oblitera-
tion of capillary lumen with accumulation of PAS-positive
material in part or the whole glomerular tuft, with or
without adhesion to Bowman’s capsule) were evaluated.
Severity of glomerulosclerosis was evaluated using an in-
dex score that includes the percent of glomeruli show-
ing sclerosis and the extension of the glomerulosclerosis
within the glomeruli [16] and used by us in previous com-
munications [17–19]. Briefly, glomeruli were graded from
0 to +4: grade 0, normal; grade 1, <25% involvement of
Table 1. General data of obese and lean Zucker rat groups prior to
the experiments
Lean Obese
(N = 5) (N = 5) P value
Body weight g 175 ± 3.9 221 ± 11.0 <0.01
Systolic blood pressure mm Hg 126 ± 2.5 118 ± 5.7 NS
Plasma creatinine md/dL 0.12 ± 0.02 0.12 ± 0.02 NS
Cholesterol mg/dL 71 ± 4.2 96 ± 3.9 <0.01
Triglycerides mg/dL 63 ± 7.13 244 ± 31.9 <0.001
Blood sugar mg/dL 105 ± 13.8 211 ± 21.5 <0.01
Proteinuria mg/24 hours Negative Negative NS
Glomerulosclerosis index score 0 0 NS
Tubulointerstial damage score 0 0 NS
Studies were done in 7-week-old rats. Tubulointerstitial and glomerulosclerosis
damage scores are described in the text.
the glomerular tuft; grade 2, 25% to 50% involvement
of the glomerular tuft; grade 3, 50% to 75%; and grade
4, sclerosis occupying >75% of the glomerular tuft. The
glomerulosclerosis score was obtained as follows: (1 ×
number of glomeruli with+1)+ (2×number of glomeruli
with +2) + (3 × number of glomeruli with +3) + (4 ×
number of glomeruli with +4)/total number of glomeruli
examined. All glomeruli suitable for analysis were exam-
ined in each biopsy (range32 to 66).
Tubulointerstitial damage (infiltration, fibrosis, tubu-
lar dilatation, or atrophy) was evaluated semiquantita-
tively as in previous investigations [17–19], in which the
grading was done according to the extension of the dam-
aged tubulointerstitial area in the renal cortex: 0, normal;
grade 1, <10%; grade 2, 10% to 25%; grade 3, 25% to
50%; grade 4, 50% to 75%; and grade 5, 75% to 100%.
The extension of the damage was evaluated selecting vi-
sually the injured areas in successive fields in the cortical
and juxtamedullary areas of each biopsy using computer-
assisted analysis of digitalized images (Olympus BX51
System Microscope and DP70 Microscope Digital Cam-
era, with software of Sigma Pro) (Leesburgh, VA, USA).
Immunoperoxidase methodology was used to identify
lymphocytes (CD5-positive cells), macrophages (ED1-
positive cells) as detailed previously [20]. Cellular infil-
tration was evaluated separately in the glomeruli and in
tubulointerstitial areas and expressed as positive cells per
glomerular cross section (gcs) or positive cells per mm2,
respectively
Antisera
Anti-CD5 and anti-ED1 monoclonal antibodies
(Biosource, Camarillo, CA, USA) were used to identify
lymphocytes and macrophages, respectively. Secondary
biotin-conjugated affinity-pure antibodies with minimal
reactivity to rat serum proteins were purchased from
Accurate Chemical and Scientific Co. (Westbury, NY,
USA). Nonrelevant antibodies were used for negative
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Table 2. Renal function and biochemical parameters prior to sacrifice
Lean Zucker rat Obese Zucker rat Losartan MMF Losartan + MMF
Body weight g 423 ± 8 687 ± 10.5 631 ± 43.9 595 ± 13.9 585 ± 11.9a
Systolic blood pressure mm Hg 131.4 ± 8.43 155 ± 9.98 101 ± 8.46c 130 ± 6.49 125.8 ± 6.19
Plasma creatinine mg/dL 0.30 ± 0.1 0.30 ± 0.2 0.14 ± 0.04 0.14 ± 0.02 0.18 ± 0.05
Cholesterol mg/dL 79 ± 6 164 ± 12.5 117 ± 12a 112 ± 9a 104 ± 7b
Triglycerides mg/dL 87 ± 18 549 ± 105 507 ± 64 444 ± 64 346 ± 48
Blood sugar mg/dL 218 ± 14 277 ± 54.1 256 ± 56 272 ± 24.1 340 ± 19
N = 5 all animal groups.
aP < 0.05; bP < 0.01; cP < 0.001 vs. obese Zucker rat in multigroup analysis of variance (ANOVA) analysis. Rats of the lean Zucker rat group are listed for
comparison purposes.
control studies. Immunohistologic techniques have been
reported previously [12, 17, 18, 20]
Statistical analysis
Comparison between the experimental groups were
done with multigroup analysis of variance (ANOVA)
methodology. When results indicated P < 0.05, Tukey
post hoc tests were used to analyze individual group dif-
ferences. Results are expressed as mean ± SEM. Two-
tailed P values <0.05 are considered significant.
RESULTS
General data
Table 1 shows the body weight, blood pressure, and
biochemical parameters in the obese Zucker rat and lean
Zucker rat groups prior to the study. As shown, the obese
Zucker rat group had higher body weight, plasma choles-
terol, triglycerides, and glucose concentrations than those
found in the lean Zucker rats.
Table 2 shows the clinical and biochemical data at the
end of the study. As expected, obese Zucker rats had in-
creased weight, blood pressure, and plasma lipids than
the lean Zucker rat counterparts. While serum creatinine
was similar in obese Zucker rats and lean Zucker rats,
the proteinuria was significantly increased in the obese
Zucker rats. No significant differences were observed in
the plasma creatinine levels in the obese Zucker rat, losar-
tan, MMF, and losartan + MMF groups (Table 2).
The effects of losartan, MMF, and the combination of
these treatments on the proteinuria in the obese Zucker
rats are shown in Figure 1. While a reduction in protein-
uria was observed with losartan (P < 0.05) and to a lesser
degree with MMF administration alone, the maximal ef-
fect on proteinuria was observed with the combination of
AT1 receptor blockade and MMF treatment that resulted
in nearly 50% reduction in the urinary protein excretion
(P < 0.01) (Fig. 1).
Histology and immunohistology
Light microscopy was normal in the lean Zucker rat
group; in contrast, significant glomerular and tubulointer-
stitial damage was evident in the untreated obese Zucker
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Fig. 1. Proteinuria in the obese Zucker rat (OZR) groups at the end of
the experiments. There is a reduction of proteinuria with losartan (Lo)
treatment, and most marked with the combination of mycophenolate
mofetil (MMF) and losartan (Lo + MMF). ∗P < 0.05; ∗∗P < 0.01 vs.
obese Zucker rat. Lean Zucker rat group had a proteinuria of 6 ± 3
mg/24 hours.
rat group (Fig. 2). Losartan administration resulted in sig-
nificant amelioration of renal histologic abnormalities in
the obese Zucker rat. The treatment with MMF reduced
significantly (P < 0.05) the histologic damage in glomeruli
and in tubulointerstitial areas in the obese Zucker rat
to values that were comparable to those found in the
losartan-treated obese Zucker rat. The beneficial effects
were more pronounced when losartan and MMF were
given in combination (losartan + MMF group) (Fig. 2).
Representative microphotographs of renal biopsies in the
untreated obese Zucker rat group (Fig. 2C and D) are
shown in comparison with renal biopsies in rats receiving
MMF alone (Fig. 2E) and in combination with losartan
(Fig. 2F).
The untreated obese Zucker rat exhibited a signifi-
cant glomerular infiltration of immune cells which was
reduced in the treated groups. The reduction in the num-
ber of macrophages infiltrating the glomeruli was partic-
ularly marked (Fig. 3A and B). Tubulointerstitial infil-
tration of lymphocytes was not significantly modified by
the treatments used (Fig. 3C); in contrast, macrophage
accumulation in tubulointerstitial areas was significantly
reduced by MMF treatment (Fig. 3D, E, and F).
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Fig. 2. Renal structural findings in the obese Zucker rat (OZR) experimental groups at the end of the study. Glomerulosclerosis index (A),
tubulointerstitial damage score (B) are reduced in the losartan (Lo) group, the mycophenolate mofetil (MMF) group, and more significantly in
the obese Zucker rat group that received MMF and losartan (Lo + MMF). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 vs. the untreated obese Zucker
rat group. Representative microphotographs of renal biopsies in the obese Zucker rat group (C and D) showing a glomeruli with focal segmental
glomerulosclerosis (arrow) and capsular adhesion (arrowhead) and numerous dilated tubules surrounding the glomerulus. The obese Zucker rat
group also had frequent tubular protein casts with small fat droplets in its interior, three of which are indicated by arrows (D). For comparison,
a renal biopsy of a rat from the losartan-treated group is shown (F), showing only mild focal hypercellularity (arrow) and the essentially normal
appearance of the biopsy of a rat treated with both MMF and losartan (E). All stainings are periodic acid-Schiff (PAS).
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Fig. 3. Glomerular (A and B) and tubulointerstitial (C and D) infiltration of immune cells in the experimental groups. Reduction of macrophages
(ED1-positive cells) was a more consistent finding, both in glomeruli and in tubulointerstitium, than the reduction in lymphocyte (CD5-positive
cells) infiltration. Representative microphotographs of the tubulointerstitial macrophage infiltration in the obese Zucker rat (OZR) (E) is reduced
by the combination of mycophenolate mofetil (MMF) and losartan (Lo) treatment (Lo + MMF) (F).
DISCUSSION
In agreement with other reports [6, 7], including our
own observations [8], suppression of the angiotensin sys-
tem ameliorates the nephropathy in the obese Zucker
rat. The new findings of this study are that treatment
with MMF also ameliorates the chronic nephropathy
in the obese Zucker rat. Previous studies have shown
that MMF treatment reduces proteinuria in immune-
mediated nephropathies, such as lupus nephropathy [21]
as well as in experimental models of nonimmune renal
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disease [11, 12]. The present studies demonstrate that
this drug improves the structural damage and proteinuria
in the obese Zucker rat and these effects are more pro-
nounced if MMF is combined with angiotensin receptor
type 1 blockade.
The additive benefits of the two treatments is ev-
idenced by the more pronounced reduction in pro-
teinuria (Fig. 1) and the greater preservation of the
kidney structure observed with the dual therapy than
with either treatment alone (Fig. 2). The infiltration of
macrophages in glomeruli and tubulointerstitial areas
was largely prevented by MMF treatment and this ef-
fect likely contributed to its beneficial effects. This is
because macrophage infiltration is a triggering event in
the development of glomerulosclerosis in this model [9].
Clearly, other effects of MMF, including its action on
resident kidney cells, particularly interstitial myofibrob-
lasts and mesangial cells [22, 23], reduction of extracel-
lular matrix proteins production [23], and stabilization
of the glomerular cytoskeleton [24], could contribute
to the improvement of the nephropathy with MMF
administration
Treatment with losartan with or without MMF low-
ered blood pressure in the treated obese Zucker rat
groups; however, the difference in blood pressure be-
tween treated and untreated obese Zucker rat reached
statistical significance only in the rats treated with losar-
tan (Table 2). The reason for the lack of significant blood
pressure reduction in the group that received both losar-
tan and MMF is not apparent.
All treated groups of obese Zucker rats exhibited sig-
nificant reductions in plasma cholesterol concentration
(Table 2). Plasma cholesterol is frequently elevated in rats
with chronic renal insufficiency [25, 26]. Therefore, im-
provement in the nephropathy as evidenced by reduction
in proteinuria and preservation of renal structure could
be, in part, responsible for the reduction in plasma choles-
terol levels in the treated obese Zucker rat groups. Similar
reductions in cholesterol have been observed in associa-
tion with the reduction of proteinuria and improvement
in glomerulosclerosis in the hyperlipemic Imai rat treated
with angiotensin receptor 1 blocker [27].
The findings of the present study point to the role of
inflammation in the pathogenesis of renal injury in the
metabolic syndrome. However, in the presence of frank
diabetes, hyperglycemia plays a major role in the devel-
opment of nephropathy and tight glycemia control is es-
sential in prevention of diabetic nephropathy.
CONCLUSION
The combination of MMF and angiotensin receptor
blockade offers significant protection against chronic
nephropathy in the obese Zucker rat.
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